We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
Cap. Flow
+$32.2M
Cap. Flow %
1.94%
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38
Avg Time Held Equity + Options
2.1 quarters
Top 10 Avg Time Held Equity + Options
2.8 quarters
Top 20 Avg Time Held Equity + Options
3 quarters
Avg Time Held Equity only
2.2 quarters
Top 10 Avg Time Held Equity only
2.9 quarters
Top 20 Avg Time Held Equity only
3 quarters

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$23.8M
2
VTRS icon
Viatris
VTRS
+$14.8M
3
EGRX icon
Eagle Pharmaceuticals, Inc.
EGRX
+$14.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
5
NVRO icon
NEVRO CORP.
NVRO
+$12.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.4M
2
BLUE icon
bluebird bio
BLUE
+$16.3M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$12.1M
4
QURE icon
uniQure
QURE
+$11.1M
5
RLYP
RELYPSA INC COM
RLYP
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 81.96%
2 Miscellaneous 17.3%
3 Consumer Staples 0.52%
4 Financials 0.09%
5 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FOLD icon
1
DELISTED
Amicus Therapeutics
FOLD
$204M 12.3%
14,439,444
– –
2014 Q1
5 quarters
NBIX icon
2
Neurocrine Biosciences
NBIX
$14.4B
$157M 9.45%
3,284,467
-456,800
-12% -$19.4M
2013 Q2
8 quarters
TVTX icon
3
Travere Therapeutics
TVTX
$4.9B
$91.7M 5.52%
2,820,875
+35,895
+1% +$983K
2014 Q1
5 quarters
SRPT icon
4
Sarepta Therapeutics
SRPT
$1.84B
$85.5M 5.15%
2,809,528
+604,876
+27% +$12.4M
2013 Q2
8 quarters
TSRO
5
DELISTED
TESARO, Inc.
TSRO
$49.1M 2.96%
835,359
-143,000
-15% -$8.21M
2013 Q2
8 quarters
DYAX
6
DELISTED
DYAX CORPORATION
DYAX
$47.3M 2.85%
1,786,315
+9,315
+0.5% +$247K
2013 Q2
8 quarters
NVRO icon
7
DELISTED
NEVRO CORP.
NVRO
$42.9M 2.59%
798,959
+241,903
+43% +$12.3M
2014 Q4
2 quarters
XNCR icon
8
Xencor
XNCR
$1.86B
$41.4M 2.49%
1,884,784
-70,001
-4% -$1.19M
2013 Q4
6 quarters
XBI icon
9
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$37.8M 2.28%
+450,000
New +$35M
2015 Q2
0 quarters
RLYP
10
DELISTED
RELYPSA INC COM
RLYP
$37.7M 2.27%
1,139,142
-315,000
-22% -$10.8M
2013 Q4
6 quarters
RXDX
11
DELISTED
Ignyta, Inc.
RXDX
$29.7M 1.79%
+1,967,600
New +$23.8M
2015 Q2
0 quarters
TLPH icon
12
Talphera
TLPH
$56.1M
$27.9M 1.68%
328,703
– –
2013 Q2
8 quarters
IOVA icon
13
Iovance Biotherapeutics
IOVA
$6.6B
$25.3M 1.52%
2,759,593
+45,044
+2% +$503K
2015 Q1
1 quarter
DSCI
14
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$25M 1.51%
348,784
+5,500
+2% +$41.4K
2014 Q1
5 quarters
GILD icon
15
PUT
Gilead Sciences
GILD
$187B
$23.4M 1.41%
+200,000
New +$21.9M
2015 Q2
0 quarters
ANIP icon
16
ANI Pharmaceuticals
ANIP
$1.69B
$20.3M 1.22%
327,157
+19,373
+6% +$1.15M
2014 Q4
2 quarters
ARAV
17
DELISTED
Aravive, Inc. Common Stock
ARAV
$20.1M 1.21%
220,233
-37,512
-15% -$3.8M
2014 Q1
5 quarters
CEMP
18
DELISTED
Cempra, Inc.
CEMP
$19.7M 1.18%
572,500
– –
2014 Q4
2 quarters
PFNX
19
DELISTED
Pfenex Inc.
PFNX
$19.6M 1.18%
1,010,877
+144,454
+17% +$2.42M
2014 Q3
3 quarters
ZSPH
20
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$19M 1.14%
361,777
+175,000
+94% +$8.62M
2015 Q1
1 quarter
EGRX icon
21
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$18.8M 1.13%
233,044
+220,956
+1,828% +$14.4M
2015 Q1
1 quarter
AGN
22
DELISTED
Allergan plc
AGN
$18M 1.08%
59,185
+10,000
+20% +$2.98M
2014 Q3
3 quarters
QURE icon
23
uniQure
QURE
$1.51B
$17.6M 1.06%
650,269
-389,063
-37% -$11.1M
2014 Q4
2 quarters
ACAD icon
24
Acadia Pharmaceuticals
ACAD
$3.34B
$17.2M 1.03%
410,240
-190,000
-32% -$7.35M
2014 Q1
5 quarters
CBPO
25
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$17M 1.02%
147,604
+77,604
+111% +$8.15M
2014 Q2
4 quarters
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors's Q2 2015 filing shows 55 new, 41 increased, 36 reduced and 38 closed positions. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M. The largest sale was Neurocrine Biosciences, an estimated $19.4M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
  • Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
  • Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
  • Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
  • Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
  • Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.

Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.